GE HealthCare Reports Q2 2026 Earnings with Mixed Performance Across Segments
GE HealthCare (GEHC) reported second-quarter earnings for fiscal year 2026, showing total revenue of $5.3 billion, a 5.7% increase from the prior year. Organic growth was driven by strong performance in Pharmaceutical Diagnostics and Advanced Imaging Solutions segments but offset by challenges in Patient Care Solutions due to supply chain issues. The company reported an adjusted EBIT margin of 14.2%, down slightly due to underperformance in one segment and inflationary pressures from memory chips, oil, and freight costs. Free cash flow was $68 million for the quarter, with tariff refunds partially offsetting working capital investments. Organic orders grew by 11.1% year-over-year, reflecting strong demand across all segments. Looking ahead, GE HealthCare provided full-year guidance of organic revenue growth between 3% and 4%, adjusted EBIT margin in a range from 15.4% to 15.7%, and adjusted EPS expected to be $4.80 to $5.00.
Tickers: $GEHC
Topics: adjusted_eps backlog ebit_margin free_cash_flow orders organic_growth revenue